Passionflower: chrysin, GABA, anxiety, and sleep—from molecule to clinical evidence

Evening calm and restorative sleep are not the same thing. Someone may feel less anxious yet still take a long time to fall asleep; sleep longer but wake unrefreshed; or feel better even though the objective structure of sleep has barely changed. These distinctions shape the scientific discussion of passionflower, or purple passionflower, Passiflora incarnata L. The plant has a history of use for nervous tension and difficulty sleeping, but the promise of “natural sleep without side effects” goes well beyond what clinical studies have established.

Passionflower is also interesting because it is a mixture of compounds that cannot be reduced to one appealing name. Chrysin has indeed been studied as a ligand at the benzodiazepine site of a receptor, but its oral bioavailability is limited. C-glycosyl flavones help characterize the plant material, but their amount is not a direct measure of an effect on the brain. A benzoflavone fraction appears in animal studies, yet those findings do not turn every pharmacy extract into a treatment for dependence. To understand these links, we first need to establish what is in a preparation, then what reaches tissues, and only then what changes patients notice.

What exactly is meant by medicinal passionflower

The pharmacognostic name Passiflorae herba refers to the dried aerial parts of P. incarnata: shoots with leaves and other above-ground organs. It is not a generic name for all plants in the genus Passiflora, nor another name for the fruit of the passion fruit. Edible P. edulis, ornamental P. caerulea, and medicinal P. incarnata differ in botanical identity, the parts used, and chemical profile. Juice from passion fruit, tea made from an unidentified garden vine, and an extract studied in a trial are therefore not interchangeable products.

Distinguishing species also matters when reading the literature. The title of an early study by Wolfman on chrysin names Passiflora coerulea, the name used by the authors for blue passionflower. The study can be discussed as research on a molecule, but it does not show that all P. incarnata preparations contain the same amount of chrysin or have the same efficacy. Likewise, finding cyanogenic compounds in members of the genus does not justify assigning one toxicity profile to every plant; the species, plant organ, and preparation method all matter.

Quality plant material is characterized by botanical identity, chromatographic profile, marker-compound content, and contaminant controls. Pharmacopoeial standardization makes batches more comparable, but it does not mean that the plant has been proven to treat an anxiety disorder. The European assessment distinguishes traditional use to relieve mild mental stress and support sleep from the status of an established clinical treatment for a disease. That distinction still applies to a product with a clear label and sound analytical quality control.

Flavonoid profile: why the sugar linkage matters

Characteristic constituents of passionflower include C-glycosyl flavones. Vitexin is apigenin-8-C-glucoside, while isovitexin is apigenin-6-C-glucoside. Orientin and isoorientin are built on the same pattern using luteolin; the position of the sugar distinguishes these isomers. Compounds with two sugar residues, including vicenin-2, schaftoside, and isoschaftoside, are also discussed. This list describes chemical diversity; it is not a set of independently proven anxiolytics.

In an O-glycoside, the sugar is linked to the aglycone through an oxygen atom. In a C-glycoside, the sugar moiety and flavone scaffold are joined by a carbon–carbon bond. This difference affects resistance to hydrolysis: ordinary enzymatic cleavage of the sugar, as occurs with O-glycosides, is more difficult. However, “resistant” does not mean completely immune to metabolism, and a C-linkage does not prove that the entire unchanged dose reaches the colon.

C-glycosides may undergo microbial transformation in the gut, producing simpler phenolic compounds. The process depends on the specific substrate, the metabolic capacity of the microbiota, and contact time. No single obligatory route can be assigned to the entire class, and listing several bacterial genera cannot guarantee the same transformation in every person. Nor does microbial metabolism automatically imply prolonged anxiolytic activity: that would require linking the preparation’s composition and metabolite concentrations to a clinical outcome.

Chrysin and benzoflavones: different levels of certainty

Chrysin is 5,7-dihydroxyflavone, with molecular formula $\\mathrm{C_{15}H_{10}O_4}$ and a molar mass of about $254.24\\ \\mathrm{g/mol}$. Its flavone scaffold contains aromatic rings and an oxygen-containing heterocyclic ring with a carbonyl group. Apigenin has an additional hydroxyl group at 4′, while luteolin has hydroxyl groups at 3′ and 4′. These differences affect polarity, protein binding, and conjugation, but do not by themselves establish a clinical advantage for one flavone over another.

Chrysin’s moderate lipophilicity makes interaction with membranes plausible. It does not, however, prove that free chrysin crosses the human blood–brain barrier after a cup of tea or a capsule. Such a conclusion would require data on unchanged chrysin in blood, its unbound fraction, transport across the endothelium, and concentrations in the brain. It would also be necessary to confirm that the particular plant material contains a meaningful amount of chrysin, rather than merely carrying the general label “passionflower.”

The benzoflavone fraction, abbreviated BZF, has a different research history. Dhawan and colleagues described isolating a fraction from an extract and studying its effects on anxiety-like behavior and certain manifestations of substance withdrawal in animals. These results support discussion of experimental targets, but do not justify treating BZF as a universal quantitative marker for all medicinal products. This line of research does not establish that a whole extract is superior to chrysin or benzodiazepines in humans.

Why passionflower should not be described as a herbal MAO inhibitor

Older passionflower literature mentions β-carbolines, including harman, harmine, harmaline, and related compounds. But the historical detection of an alkaloid and clinically meaningful monoamine oxidase inhibition after ordinary use are different claims. Contemporary preparations require information on plant identity, analytical-method sensitivity, and actual compound content. These data do not support one precise concentration for every batch.

There is no basis for transferring the pharmacological profile of Syrian rue or plants used in ayahuasca to P. incarnata. At the same time, the absence of confirmed, meaningful MAO-inhibiting activity does not mean that every passionflower product can be combined unconditionally with every antidepressant. Safety depends on the full composition, concomitant medicines, and possible drowsiness—not only on one proposed mechanism.

Between capsule and brain: chrysin’s first-pass metabolism

After absorption, flavones undergo intestinal and hepatic processing. Conjugation reactions are important for chrysin: UGT enzymes attach glucuronic acid, while SULT enzymes attach a sulfate group. These transformations can be represented schematically as follows. “Chrysin–OH” identifies the hydroxyl group involved in the reaction; it does not specify a single positional metabolite isomer.

$$\\text{Chrysin–OH}+\\text{UDP-glucuronate} \\xrightarrow{\\mathrm{UGT}} \\text{Chrysin–O-glucuronide}+\\mathrm{UDP}$$ $$\\text{Chrysin–OH}+\\mathrm{PAPS} \\xrightarrow{\\mathrm{SULT}} \\text{Chrysin–O-sulfate}+\\mathrm{PAP}$$

PAPS donates the sulfate group, and UDP-glucuronate donates glucuronic acid. Conjugation changes a compound’s solubility and transport; a conjugate cannot automatically be treated as pharmacologically equivalent to the original flavone. Some products may return to the intestine and undergo further transformation and elimination. These processes help explain why a molecule’s ability to interact with membranes does not by itself ensure high systemic exposure.

In a study by Walle and colleagues, seven healthy volunteers received a single 400 mg dose of chrysin. The maximum measured plasma concentrations of the unchanged compound were only 3–16 ng/mL, while exposure to the sulfate metabolite was substantially higher. This was a pharmacokinetic research dose, not a treatment recommendation for anxiety or insomnia; the study did not test passionflower’s efficacy. Its key finding was the low oral availability of unchanged chrysin due to extensive metabolism.

Converting units helps compare pharmacokinetic findings with laboratory experiments. At a molar mass of $254.24\\ \\mathrm{g/mol}$, the reported range corresponds to approximately $0.012–0.063\\ \\mathrm{µmol/L}$ total plasma concentration. This is a calculation from the study, not a measurement of free chrysin in the brain. A receptor effect observed at micromolar concentrations in vitro therefore cannot be assumed after oral use without additional evidence. Low exposure to the unchanged molecule also limits the transfer of laboratory findings on CYP19A1 aromatase inhibition to human hormone levels; claims that chrysin raises testosterone or controls brain neurosteroids are not supported here.

The GABA synapse: what is known about the receptor and about the extract

Gamma-aminobutyric acid (GABA) is a major inhibitory neurotransmitter in the mature nervous system. It acts through different receptors, so saying that a substance “enhances GABA” is too vague to be useful. GABA_A is a ligand-gated anion channel, whereas GABA_B is a metabotropic receptor that signals through G proteins. Effects on neurotransmitter uptake, competition at a binding site, and changes in receptor function are distinct experimental findings.

GABA_A structure and the electrical meaning of inhibition

The GABA_A receptor consists of five subunits. A common synaptic form contains two α, two β, and one γ subunit, although receptor composition varies across cells and brain regions. GABA binds at β+/α− interfaces, while the classical benzodiazepine site lies at the α+/γ− interface in benzodiazepine-sensitive receptor variants. The orthosteric site recognizes the primary neurotransmitter; an allosteric site allows another compound to modify the response to it.

When the channel opens, anion conductance across the membrane increases, mainly for $\\mathrm{Cl^-}$, with a contribution from bicarbonate. In a mature neuron, this usually lowers the probability of excitation, but it does not always produce strong hyperpolarization. A shunting effect may occur instead: an excitatory signal has more difficulty changing the membrane potential. The direction and size of the current depend on the electrochemical gradient. Thus, a value such as “below −70 mV” is not a universal consequence of GABA_A activation.

$$I_{\\mathrm{GABA_A}}=g_{\\mathrm{GABA_A}}\\,(V_m-E_{\\mathrm{GABA_A}})$$

Here, $g$ is the conductance of open channels, $V_m$ is the membrane potential, and $E_{\\mathrm{GABA_A}}$ is the reversal potential of the anion current. The equation describes a physiological principle; it is not a numerical estimate of passionflower’s effect. It shows why a change in conductance must be interpreted in the context of the cell’s state rather than described as “switching off the brain.”

Benzodiazepines are positive allosteric modulators: they enhance the effect of GABA rather than directly replacing it. Their benefits and adverse effects depend on the medicine, dose, timing, and individual. Z-hypnotics are also not a uniform group; zolpidem’s preference for α1-containing receptors cannot be generalized to every drug in the class. Real limitations of these medicines do not require describing their effects as “stupor”—that metaphor obscures differences between drugs and clinical situations.

Chrysin: a receptor ligand is not a proven selective anxiolytic

Early studies by Medina, Wolfman, and colleagues connected interest in chrysin with its interaction with central benzodiazepine sites and behavioral effects in animal models. Flavonoid studies examined anxiety-like behavior, seizure activity, and motor function. These findings matter for compound discovery, but do not establish a universal intrinsic efficacy for chrysin, expressed as an exact percentage of diazepam’s effect. Nor do they show that whole passionflower extracts increase inhibitory currents in humans by a fixed 25–45%.

A key distinction is between binding and function. Displacement of a radioligand confirms an interaction in the experimental system; by itself, it does not show whether a compound will enhance, reduce, or leave the receptor’s response unchanged. Reversal of a behavioral effect by flumazenil supports involvement of a benzodiazepine-sensitive GABAergic mechanism, but does not identify the specific active molecule in an extract or establish its exposure in humans. One such experiment cannot justify calling BZF, chrysin, and all C-glycosides equivalent low-efficacy PAMs.

Subunit biology helps explain the interest in selective modulators. α1-containing receptors contribute to sedative effects; α2/α3-containing receptors contribute to some anxiolytic effects; and α5-containing receptors are involved in hippocampal inhibition and memory processes. These are functional associations, not a strict map of “one subunit per symptom.” There is insufficient evidence that passionflower products are selectively active at α2/α3 while fully sparing α1/α5, or that they guarantee the absence of ataxia, drowsiness, or memory problems.

What the Appel and Grundmann experiments found

In the Appel study, a specific extract reduced uptake of radiolabeled GABA in synaptosomes—isolated nerve terminals. Receptor assays examined binding to GABA_A and GABA_B, while a functional G-protein activation assay indicated GABA_B antagonism. The study did not show the claimed effect of that extract at the GABA_A benzodiazepine site. These findings therefore do not support the simple claim that “the extract activates every inhibitory receptor.”

In a mouse study by Grundmann and colleagues, a different, chemically characterized extract was used. Orientin, homoorientin, vitexin, and isovitexin were among its principal identified constituents. Flumazenil, but not a 5-HT1A antagonist, blocked the anxiolytic-like behavioral effect; the dose-response curve was U-shaped. This supports involvement of the GABAergic system in that particular model. The difference from Appel’s findings underscores the importance of extraction, composition, and experimental method; it does not allow one experiment to be declared the universal mechanism of the plant.

Rat studies have also examined spatial memory, stress-related behavior, and changes in neurotransmission after passionflower exposure. They broaden the experimental picture, but performance in a maze is not equivalent to measuring human memory, and a change in a neurotransmitter marker does not establish a clinical mechanism. Likewise, animal sleep experiments cannot substitute for polysomnography in patients. They do not show that memory will necessarily remain intact in people taking an extract or that a particular sleep stage will increase.

The practical implication is that these results have limited transferability. A change in uptake at rat nerve terminals does not prove that a compound in a capsule blocks a specific GAT transporter in the human brain. GABA detected in a plant product is likewise not evidence that it enters the central nervous system. Related questions about peripheral receptors and the blood–brain barrier are discussed in the article on exogenous GABA; that context helps prevent conflating extract pharmacology with the pharmacology of a single neurotransmitter.

Sleep needs to be measured in more than one way

Less tension at bedtime may make it easier to fall asleep, but that plausible link does not establish that the entire architecture of sleep has been restored. Polysomnography combines electroencephalography, eye movements, and muscle activity with breathing and other signals. Subjective sleep quality answers a different question: how a person experiences the night and feels afterward. These methods complement one another, but a positive diary entry cannot be relabeled as an increase in deep sleep.

NREM, REM, and study endpoints

NREM sleep is divided into stages N1, N2, and N3. N1 is the transition into sleep; N2 is characterized by sleep spindles and K-complexes; and N3 contains prominent slow-wave activity. REM sleep features rapid eye movements, a distinctive electroencephalographic pattern, and reduced tone in most skeletal muscles. The stages cycle through the night, but their duration and proportions vary with age, prior wakefulness, and health.

Slow-wave sleep is associated with restorative and plasticity-related processes, while different stages contribute to memory and emotional processing. Sleep research also examines the movement of fluid and metabolites in the brain, including glymphatic mechanisms. However, these general ideas do not justify claiming that passionflower increases β-amyloid or tau clearance in humans. Likewise, a proposed link between N3 and growth-hormone secretion does not prove an anabolic effect of a supplement.

$$\\text{Sleep efficiency}=\\frac{\\text{TST}}{\\text{time in bed}}\\times100\\%$$

Interpretation requires distinguishing change from baseline from an advantage over placebo. Patients in both groups may sleep better because they are participating in a study, expect benefit, change their routine, or experience natural symptom fluctuations. A statistically significant before-and-after change in one group therefore does not prove a specific effect of the product. Another separate question is whether the improvement is noticeable in daily life and persists after a short course ends.

Tea and extract: two different clinical observations

Ngan and Conduit studied passionflower tea and subjective sleep quality. This supports discussion of a possible benefit from that particular infusion under the conditions studied, but does not show that every concentrated capsule has the same effect. Nor can a subjective rating establish preserved REM sleep, increased delta power, or the absence of residual morning effects. Polysomnographic measures and sleep diaries should be described separately, in proportion to the evidence available for each.

Lee and colleagues studied 110 adults with insomnia disorder who received an extract or placebo for two weeks. Total sleep time changed by $23.05\\pm54.26$ minutes in the passionflower group and $-0.16\\pm53.12$ minutes in the placebo group, with a between-group $p=0.049$. Sleep efficiency and WASO improved within the extract group, but no advantage over placebo was found for those outcomes. This is a positive signal for TST amid substantial variability, not evidence that every sleep stage was restored.

The short follow-up limits conclusions about durability. The study does not establish a universal 20–40% reduction in SOL, guaranteed preservation of REM/N3, increased glymphatic clearance, or complete absence of morning drowsiness. Nor can the results in adults be transferred to children, pregnant people, or every other passionflower product. “A possible modest improvement in selected sleep parameters” is more faithful to the evidence than a promise of a physiological reset.

The stress axis: a plausible link that requires its own evidence

Anxiety, vigilance, and waking during the night may be sustained by stress-response systems. In the hypothalamic–pituitary–adrenal axis, corticotropin-releasing hormone (CRH) stimulates ACTH release, and ACTH stimulates cortisol secretion by the adrenal glands. The locus coeruleus contributes to noradrenergic regulation of wakefulness. These systems are related but not identical, and each episode of nighttime wakefulness is not a measured “cortisol surge.”

$$\\text{Hypothalamus: CRH}\\rightarrow\\text{Pituitary: ACTH}\\rightarrow\\text{Adrenals: cortisol}$$

The general role of GABA in regulating stress networks makes it possible to hypothesize that passionflower might affect hyperarousal. But the clinical studies discussed here do not establish that an extract directly inhibits neurons in the human paraventricular nucleus, flattens the nighttime cortisol profile, or increases vagal activity. Heart-rate variability also depends on breathing, posture, time of day, and analytical method; it is not ready-made proof that a product “activates the parasympathetic system.” These mechanisms remain questions for studies designed to measure them.

Anxiety in clinical settings: four weeks of treatment and minutes before a procedure

The evidence on passionflower for anxiety spans different situations: persistent anxiety disorders and brief distress before a procedure. A shared symptom does not make these the same clinical problem. For generalized anxiety, relevant outcomes include sustained response, day-to-day functioning, and relapse prevention. Before surgery, the aim is to reduce distress in a controlled way while preserving the safety of anesthesia and recovery. A result in one setting cannot be transferred directly to the other.

What the comparison with oxazepam means

In a pilot trial by Akhondzadeh and colleagues, 36 patients with generalized anxiety disorder were assigned for four weeks to a liquid passionflower extract (45 drops per day) or oxazepam (30 mg per day), with corresponding placebos. At the end of the study, no significant difference in anxiety was detected between the groups. Oxazepam began to act faster, and work impairment was reported more often in its group. This is a meaningful research signal, but it does not prove therapeutic equivalence.

Failure to detect a statistically significant difference and proof of equivalence are different results. Equivalence requires a specifically designed study with prespecified margins and enough participants. A small pilot trial does not establish that the medicines are equal for severe symptoms, prolonged treatment, or relapse prevention. Nor does it turn the number of drops in one liquid formulation into a universal dose for all extracts, or prove the complete absence of cognitive adverse effects.

What can be carried over from surgery and dentistry

A placebo-controlled study by Movafegh examined a single dose of passionflower before ambulatory surgery. Aslanargun and colleagues studied anxiety before spinal anesthesia. These trials support interest in particular products within medical procedures; their results must be interpreted in light of the anxiety scales, assessment times, patient characteristics, and anesthesia protocols. They do not provide a basis for self-administering a premedication before a procedure.

A crossover dental trial by Dantas included 40 participants. Before extraction of impacted mandibular third molars, the study compared 260 mg of passionflower with 15 mg of midazolam. Under both protocols, many participants described themselves as calm or mildly anxious; with midazolam, 20% reported not remembering the procedure. Passionflower was not free of sedative effects, however: drowsiness was recorded in 50% of participants during the passionflower protocol in the adverse-event table. This finding contradicts a promise of zero drowsiness, although its frequency cannot be generalized to every formulation and setting.

Systematic reviews by Janda and a clinical review by Miroddi bring these strands of literature together, but synthesis does not remove differences among products and study designs. Small samples, varied endpoints, and short follow-up limit the strength of conclusions. A section called “evidence base” should therefore not obscure that clinical certainty remains far lower than the appeal of the molecular hypotheses.

BZF, tolerance, and withdrawal: why an animal model is not a treatment protocol

In Dhawan’s research, the benzoflavone fraction was studied in relation to anxiety-like behavior during alcohol cessation in mice and other models of dependence. These are specific experimental conditions: a defined fraction, controlled administration, a set withdrawal period, and behavioral criteria. Reducing one sign in such a model does not mean dependence as a disorder has been treated. Nor does it establish that the effect occurs in every extract standardized for flavonoids.

Research on tolerance requires the same distinctions. With prolonged exposure, receptors and neural networks may adapt, but the mechanism depends on the compound and regimen. Calling chrysin a “mild” modulator is not enough to conclude that it does not cause receptor phosphorylation, internalization, or other adaptations. A proposed effect of BZF on aromatase and neurosteroids does not prove prevention of tolerance in humans; the relevant concentrations, active molecule, and clinical outcome must be established separately.

There is no basis for assigning passionflower a “zero addiction index.” The absence of a well-established risk comparable to that of benzodiazepines is different from proof of no risk after months or years of use. Small, short studies cannot rule out rare adverse events or adequately evaluate stopping long-term use. At the same time, the need to taper a prescribed benzodiazepine depends on that medicine’s own risks; passionflower extract is not a reason to stop it abruptly.

Detoxification after alcohol or opioid use and benzodiazepine withdrawal require clinical care. Animal experiments with BZF do not provide a home protocol and do not show protection from seizures or other serious complications. Passionflower can be discussed as an adjunct only within a specific medical decision; it should not be credited with independently treating withdrawal. This preserves the scientific value of the experimental work without turning it into a dangerous promise.

How to read a preparation, not just the plant name

Two packages labeled “passionflower 300 mg” may contain different products. One may state the mass of powdered herb, another the mass of dry extract, and a third a blend with excipients. The extraction solvent, drug-to-extract ratio, chemical profile, and other ingredients determine how comparable a product is to one used in a study. A milligram amount is meaningful only alongside these details.

DER and quality markers

DER is the ratio of the amount of starting plant material to the amount of extract obtained. For a native dry extract, excluding added excipients, it can be expressed as a ratio of masses. It is important to establish whether the stated value refers to the native extract or to the finished mixture; otherwise, a simple comparison between packages may be misleading.

$$\\mathrm{DER_{native}}=\\frac{m_{\\text{initial dried plant material}}}{m_{\\text{native extract}}}$$

For example, a 5:1 designation means that five parts by mass of plant material were used to produce one part of native extract. It does not mean five times the clinical effect, nor does it prove superiority over a product with a different DER. An aqueous infusion and a hydroalcoholic extract may recover compounds in different proportions; a higher yield of some constituents is not equivalent to a better outcome. A universal “optimal DER of 4:1–10:1,” detached from a particular product, is therefore not a justified selection rule.

An assay reporting total flavonoids as vitexin equivalents expresses an analytical result against a chosen reference standard. It does not mean that all measured flavonoids are vitexin, nor does it guarantee a known dose of chrysin or BZF. Appropriate chromatographic methods are used to establish the profile; quantitative results should be read together with the method and specification. Pharmacopoeial requirements for the herb and commercial claims about extracts should not be merged into an arbitrary percentage of “activity.”

Quality control means meeting specified limits under an analytical procedure, not literal “absolute absence” of every trace contaminant. For heavy metals, pesticides, and microbial contamination, the applicable limit, method, and actual batch documentation matter. A high total-flavonoid figure alone establishes neither purity nor efficacy.

Why there is no universal daytime or bedtime dose here

Studies used different liquid and solid formulations, and brief premedication differed from a course for anxiety or insomnia. The 45 drops, 260 mg, and other regimens reported in this article describe specific studies. They cannot be converted into one another without knowing the product’s composition, concentration, and characteristics. In particular, 400 mg of pure chrysin in a pharmacokinetic study is not equivalent to 400 mg of passionflower.

The available evidence therefore cannot yield a universal dose of 150–250 mg several times a day or 300–500 mg at bedtime. Practical use should follow the instructions for a specific registered product and take the clinical purpose into account. Timing should not be explained by a guaranteed release of receptors by morning or by one half-life assigned to the entire mixture. A multi-compound extract cannot be represented by a single such constant.

It is useful to decide in advance what would count as improvement: less time to fall asleep, less wakefulness during the night, or less tension without daytime drowsiness. A sleep and well-being diary can track these changes, but it does not measure REM/N3 stages. If marked anxiety or insomnia persists, identifying the cause matters more than endlessly increasing a dose. For chronic problems, clinical assessment, behavioral approaches, and appropriate treatment should be considered rather than replaced with a plant mixture.

Combinations: biochemical plausibility and real-world tolerability

Combining several “calming” substances can look convincing on a diagram: one acts at a receptor, another affects neurotransmitter metabolism, and a third influences excitatory signaling. In the body, these pathways do not add up like numbers. Exposure, timing, target location, and adverse effects differ; a combination may increase drowsiness before it improves sleep. Separate studies of individual ingredients do not prove that a finished combination is synergistic.

Valerian and passionflower

Valerian contains compounds studied for effects on GABAergic signaling, including receptor modulation and aspects of neurotransmitter metabolism. But it is too categorical to describe valerenic acid as a proven selective GABA transaminase inhibitor in a clinically used mixture. Still less can this mechanistic account establish an optimal pairing of “250 mg passionflower plus 200 mg valerian.” A combination product must be assessed as a product in its own right, with its own evidence.

Even if both ingredients are associated with inhibitory signaling, the clinical effect need not increase in a beneficial direction. Daytime sluggishness or poor tolerability may become more pronounced, and it may be harder to identify each ingredient’s contribution. When combining products, it is therefore important to know their composition and observe the person’s actual response, rather than treating a shared GABA target as a guarantee of safety.

Magnesium and the glycine moiety

$\\mathrm{Mg^{2+}}$ participates in the physiological, voltage-dependent block of the NMDA receptor pore. This is an established principle of neurophysiology, but it does not prove that magnesium supplementation in someone without a deficiency will enhance passionflower’s effect or increase N3 sleep. Correcting magnesium deficiency and treating insomnia may be related goals, but they are not the same indication. A salt form should not be chosen on the promise of a “deep inhibitory cascade.”

Glycine is a distinct molecule with inhibitory receptors and a role as an NMDA co-agonist. But the amount of glycine in a serving of magnesium bisglycinate and its resulting exposure do not allow findings on free glycine to be transferred automatically. Explaining sleep solely through activation of strychnine-sensitive receptors or a drop in temperature is too narrow. The mechanisms are discussed further in the article on glycine, NMDA, and thermoregulation; practical magnesium replacement is covered in the article on magnesium.

Apigenin and L-theanine

Chrysin and apigenin are structurally related but not interchangeable. Apigenin is discussed in connection with receptor effects and experimental influence on CD38, which is involved in NAD$^+$ metabolism. These findings do not show that adding apigenin to passionflower will resolve evening rumination by “sparing NAD$^+$.” An established clinical causal link is missing from this chain, and it does not define a dose for a finished combination.

L-theanine has been studied in relation to stress and selected electroencephalographic measures. A change in alpha activity is not a universal marker of anxiolytic treatment or a guarantee of alertness without drowsiness. Experimental interactions with glutamatergic signaling likewise cannot be described as proven clinical blockade of AMPA/kainate receptors after an ordinary supplement dose. The articles on apigenin and L-theanine add context; they are not recommendations to combine all three substances automatically.

Safety without promising zero risk

The most practical risk of passionflower is impaired alertness and poorer tolerability, especially in combinations. Drowsiness and dizziness are possible, so an individual response cannot be predicted from the word “natural.” Other sedatives, alcohol, pain medicines, and ingredients in multi-component products deserve particular attention. Before anesthesia, tell the medical team about all supplements rather than independently repeating a regimen from a premedication study.

Drug interactions

Combining passionflower with benzodiazepines, Z-hypnotics, barbiturates, opioids, or other central nervous system depressants may increase unwanted sedation. The extent depends on the product and situation; the absence of a dedicated study of a particular pair does not make the combination safe. Using passionflower while reducing a prescribed medicine requires a separate plan with a clinician. Passionflower does not authorize changing a dose or stopping a medicine on one’s own.

Laboratory findings have reported interactions between flavonoids and CYP enzymes, including CYP3A4 and CYP2C9. But inhibition in a test tube does not determine the size of an interaction in people without assessing achievable concentrations. Presystemic conjugation may limit exposure, but it is not universal proof that every interaction of the whole mixture is absent. For medicines with a narrow therapeutic range, including warfarin, the supplement’s actual composition should be reviewed; a clinically established magnitude of interaction cannot be assigned here.

The same distinction applies to proposed effects of flavonoids on platelets. Experimental activity of an individual compound does not prove that standard passionflower products cause clinically significant bleeding. However, complex medication regimens and an unknown mixture warrant assessment before combining the product with anticoagulants or antiplatelet medicines. This is a boundary of current knowledge, not a reason to label all flavonoids either dangerous or entirely neutral.

Who needs particular caution

Safety during pregnancy and breastfeeding has not been established, so the European monograph does not recommend use. Evidence is insufficient for children younger than 12; the age limit for traditional use is not evidence of efficacy for pediatric anxiety disorders. Hypersensitivity is a contraindication. The product may impair the ability to drive or operate machinery; if this occurs, those activities should be avoided.

The monograph also advises consulting a doctor or qualified healthcare professional if symptoms persist for more than two weeks or worsen. This is not a proven two-week maximum for every course; it is a reason to reassess self-treatment. Historical reports that certain herbal preparations may stimulate the uterus should not be attributed to every purified extract, but the absence of confirmation of that effect does not fill the safety-data gap in pregnancy.

What remains of the promise of “calm without changing sleep”

Passionflower has a substantial scientific history: botanically defined plant material, a complex flavonoid profile, experimental interaction with GABAergic signaling, and small clinical trials for anxiety and sleep problems. None of these lines of evidence requires claims of proven α2/α3 selectivity, zero dependence, or complete preservation of REM and N3. On the contrary, understanding the differences between a molecule, an extract, and a specific clinical protocol makes the discussion more useful in practice.

For a patient, the central question is whether a particular product helps in a particular situation—and at what cost to daytime functioning. For a clinician, the questions also include composition, achievable exposure, control group, selected outcome, and follow-up duration. Passionflower may be a reasonable topic to discuss for mild tension and sleep difficulties, but the evidence does not justify using it in place of treatment for an anxiety disorder, chronic insomnia, or dependence. This precision preserves scientific interest in the plant without turning experimental neuropharmacology into a clinical promise.